➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Johnson and Johnson
Moodys
Boehringer Ingelheim
AstraZeneca

Last Updated: March 4, 2021

DrugPatentWatch Database Preview

MINOCIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Minocin patents expire, and what generic alternatives are available?

Minocin is a drug marketed by Bausch, Triax Pharms, Lederle, and Rempex Pharms. and is included in five NDAs. There are two patents protecting this drug.

This drug has thirty patent family members in twenty-two countries.

The generic ingredient in MINOCIN is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

Summary for MINOCIN
International Patents:30
US Patents:2
Applicants:4
NDAs:5
Suppliers / Packagers: 2
Bulk Api Vendors: 36
Clinical Trials: 35
Patent Applications: 4,087
Formulation / Manufacturing:see details
Drug Prices: Drug price information for MINOCIN
What excipients (inactive ingredients) are in MINOCIN?MINOCIN excipients list
DailyMed Link:MINOCIN at DailyMed
Drug patent expirations by year for MINOCIN
Drug Prices for MINOCIN

See drug prices for MINOCIN

Drug Sales Revenue Trends for MINOCIN

See drug sales revenues for MINOCIN

Recent Clinical Trials for MINOCIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sun Yat-sen UniversityPhase 2
St. Louis Children's HospitalPhase 2
University of WashingtonPhase 2

See all MINOCIN clinical trials

Pharmacology for MINOCIN

US Patents and Regulatory Information for MINOCIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch MINOCIN minocycline hydrochloride CAPSULE;ORAL 050649-001 May 31, 1990 AB RX Yes No   Start Trial   Start Trial   Start Trial
Rempex Pharms MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
Triax Pharms MINOCIN minocycline hydrochloride CAPSULE;ORAL 050315-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Rempex Pharms MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bausch MINOCIN minocycline hydrochloride CAPSULE;ORAL 050649-003 Feb 12, 2001 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Harvard Business School
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.